Prostatic specific antigen, screen

Alphabetical Test listing

Prostatic specific antigen, screen-1102

  
Prostatic specific antigen, screen
  
1102
  
G0103.0
  
PSS
  
PSA
  

The test method changed on 1/3/2023. If this test has been used for serial monitoring, rebaselining is recommended. Rebaselining consists of 2 measurements, collected 3-6 weeks apart.
The Roche Elecsys CEA assay is an electrochemiluminescence immunoassay "ECLIA" performed on the Roche Cobas "e" immunoassy analyzers.
Values obtained with different assay methods may be different and cannot be used interchangeably.

  
Serum
  
  
1.0 mL
  
0.2 mL
  

Immediatley following collection, mix sample by inverting 5 times

  
  1. Allow sample to clot for a minimum of 30 minutes
  2. Spin within two (2) hours of sample collection
  

Gold serum separator (SST) tube

 

 

  
Serum
Lithium heparin (Li hep) plasma
  

Immediatley following collection, mix sample by inverting 5 times

  

Red:

  1. Allow sample to clot
  2. Spin
  3. Transfer serum to a False bottom plasma/serum transport vial/tube (AHL), labelled as serum, within two (2) hours of sample collection

Lt green:

  1. Spin within two (2) hours of sample collection
  
  

Refrigerated (preferred) - 5 days

Frozen - 6 months

Ambient - 24 hours

  
  • Improper labels (unlabeled or mislabeled)
  • Hemolysis (some procedures)
  • Improper anticoagulant or ratio
  • Delay in transport
  • Improper storage temperature affecting results
  • Improper container
  • Leaking container resulting in compromised specimen
  • Quantity not sufficient (QNS)
  
AHL - Chemistry: C
  
Daily
  
1 - 2 days
  

Electrochemiluminescence immunoassay (ECLIA)

  
Up to 60 years < 3.89 ng/mL
60 - 70 years < 5.40 ng/mL
> 70 years < 6.22 ng/mL
  

In patients with total PSA concentrations between 4.0 and 10.0 ng/mL, the Prostate Health Index (PHI) may aid in distinguishing prostate cancer from benign prostate conditions.

  
G0103
  
Yes
  
  
11/30/2001
  
05/23/2024
  
05/10/2024